The topical application of nerve growth factor as a pharmacological tool for human corneal and skin ulcers

被引：86

作者：

Aloe, Luigi ^{[1
]}

Tirassa, Paola ^{[1
]}

Lambiase, Alessandro ^{[2
]}

机构：

[1] CNR, Inst Neurobiol & Mol Med, NGF Sect, I-00413 Rome, Italy

[2] Univ Rome, Rome, Italy

来源：

PHARMACOLOGICAL RESEARCH | 2008年 / 57卷 / 04期

关键词：

neurotrophins; cutaneous ulcers; epithelial cells; eye; topical application;

D O I：

10.1016/j.phrs.2008.01.010

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Aim: The nerve growth factor is a soluble protein produced by and acting upon a number of different cells located in the nervous, endocrine and immune systems. Recent studies have shown that nerve growth factor (NGF) exerts a critical role on epithelial cells and fibroblasts under normal and pathological conditions. In this review, we present data prospecting the clinical potentiality of NGF in cutaneous and ocular "non-healing" chronic ulcers. Data synthesis: A consistent number of in vitro and in vivo studies carried out on animal models and in humans indicated that fibroblasts and epithelial cells are receptive to the action of NGF and that NGF promotes skin and cornea ulcer healing. These observations lead to the hypothesis that NGF can be a potential useful pharmacological agent for clinical investigations. Conclusion: The available clinical evidences suggest that the topical application of NGF promotes healing action without side effects on corneal and cutaneous tissues damaged by chemical, physical and surgical insults and autoimmune disorders. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：253 / 258

页数：6

共 44 条

[1] Lower-extremity amputation in diabetes - The independent effects of peripheral vascular disease, sensory neuropathy, and foot ulcers [J].

Adler, AI ;

Boyko, EJ ;

Ahroni, JH ;

Smith, DG .

DIABETES CARE, 1999, 22 (07) :1029-1035

[2]

Aloe L, 2004, PROG BRAIN RES, V146, P515

[3] Nerve growth factor in neurological and non-neurological diseases: Basic findings and emerging pharmacological prospectives [J].

Aloe, L ;

Tirassa, P ;

Bracci-Laudiero, L .

CURRENT PHARMACEUTICAL DESIGN, 2001, 7 (02) :113-123

[4]

Aloe L., 2004, PROG BRAIN RES, P146

[5] The role of endogenous nerve growth factor in human diabetic neuropathy [J].

Anand, P ;

Terenghi, G ;

Warner, G ;

Kopelman, P ;

WilliamsChestnut, RE ;

Sinicropi, DV .

NATURE MEDICINE, 1996, 2 (06) :703-707

[6] Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy [J].

Apfel, SC ;

Kessler, JA ;

Adornato, BT ;

Litchy, WJ ;

Sanders, C ;

Rask, CA .

NEUROLOGY, 1998, 51 (03) :695-702

[7]

Apfel SC, 2002, INT REV NEUROBIOL, V50, P393

[8] Effect of topical application of nerve-growth factor on pressure ulcers [J].

Bernabei, R ;

Landi, F ;

Bonini, S ;

Onder, G ;

Lambiase, A ;

Pola, R ;

Aloe, L .

LANCET, 1999, 354 (9175) :307-307

[9] SENSORY DENERVATION OF THE RABBIT CORNEA AFFECTS EPITHELIAL PROPERTIES [J].

BEUERMAN, RW ;

SCHIMMELPFENNIG, B .

EXPERIMENTAL NEUROLOGY, 1980, 69 (01) :196-201

[10] NERVE GROWTH FACTOR - PURIFICATION AS A 30,000-MOLECULAR-WEIGHT PROTEIN [J].

BOCCHINI, V ;

ANGELETTI, PU .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1969, 64 (02) :787-+

← 1 2 3 4 5 →